Company: DRTSW
Filing Date: 2025-04-28
Form Type: 424B5
Source: 0001213900-25-035799
Chunk: 24

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-04-28
Form: 424B5
Chunk 24
---
 |

<div align='center'>S-13

DILUTION</div>

If you invest in our shares
in this offering, your ownership interest will be immediately diluted to the extent of the difference between the offering price per ordinary
share and the net tangible book value per ordinary share after this offering. Our net tangible book value as of December 31, 2024 was
$0.89 per ordinary share.

After giving effect to
the sale of shares that we are offering to the Investor at the offering price of $2.612 per share, after deducting the estimated offering
expenses payable by us, our net tangible book value on an adjusted basis as of December 31, 2024 would have been $1.18 per ordinary share.
This amount represents an immediate increase in net tangible book value of $0.29 per ordinary share to our existing shareholders and an
immediate dilution of $1.44 per ordinary share to the Investor purchasing shares in this offering. We determine dilution by subtracting
the as adjusted net tangible book value per share after this offering from the amount of cash that a new investor paid for a share.

The following table illustrates
this dilution:

| Offering price per share                                                    |     |   |      |     | $ | 2.612 |
| Net tangible book value per share as of December 31, 2024                   |     | $ | 0.89 |     |   |       |
| Increase in net tangible book value per share attributable to this offering |     |   | 0.29 |     |   |       |
| As adjusted net tangible book value per share after this offering           |     |   |      |     |   |  1.18 |
| Dilution per share to the Investor in this offering                         |     |   |      |     | $ |  1.44 |

The number of ordinary
shares outstanding after this offering excludes shares issuable upon exercise of the existing warrants.

To the extent any of our
outstanding options or existing warrants are exercised or RSUs vest, there will be further dilution to new investors.

<div align='center'>S-14

DESCRIPTION OF THE SECURITIES WE ARE OFFERING</div>

We are offering 14,110,121 ordinary shares through this prospectus
supplement and the accompanying prospectus and a share purchase agreement, dated April 24, 2025, between us and the Investor. The purchase
price for each share is